(AOF) – OPM (Oncodesign Precision Medicine) announces the conclusion of a financing agreement for an amount of 6 million euros granted by three regional banks: Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole Champagne Bourgogne and Société Générale . The company specializing in precision medicine for the treatment of resistant and metastatic cancers specifies that this “non-dilutive” financing is guaranteed by Bpifrance and brings OPM’s cash flow to 13.35 million euros as of 03/10/2023
“This financing allows us to calmly continue the development of OPM-101 towards phase II without losing time due to the prevailing stock market sluggishness,” declares CEO Philippe Genne. “We appreciate this mark of trust emanating from our regional ecosystem which demonstrates its support and strong conviction in OPM’s value creation project.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.